Knobbe Martens’ Standout Life Sciences Work Recognized in Annual LMG Rankings
Firm receives top-tier rankings for patent strategy, prosecution and litigation across life sciences industry IRVINE, Calif., October 1, 2025 – Knobbe Martens is proud to share that Legal Media Group...
Knobbe Martens Celebrated as “Excellent IP Firm,” Dozens of Partners Recognized for Top-Tier Patent Work in IAM Patent 1000 Guide
IRVINE, Calif., June 3, 2025 – Knobbe Martens is pleased to share that the firm and two dozen of its partners from offices throughout the country have been featured in...
Sixteen Knobbe Martens Lawyers Named Among Intellectual Property Leaders by WIPR
IRVINE, Calif., May 19, 2025 – Knobbe Martens is proud to share that 16 of the firm’s lawyers have been recognized in the World Intellectual Property Review [WIPR] 2025 Leaders...
Renewed Efforts in Congress for Pharmaceutical Patent Reform
With the recent convocation of the 119th Congress, a change in administration, and resignation of USPTO Director Vidal, pharmaceutical patent reform is likely on the minds of many in Washington....
Knobbe Martens Again Honored as a Top Life Sciences Firm by LMG
IRVINE, Calif., October 16, 2024 – Knobbe Martens’ across-the-board strength in the life sciences space was again recognized by Legal Media Group (LMG), as the firm and its partners received...
Allergan v. MSN Laboratories: Federal Circuit Places Limits on Obviousness-Type Double Patenting
On August 13, 2024, the Federal Circuit issued its decision in Allergan USA, Inc. v. MSN Laboratories Private Ltd., No. 24-1061, which limits the scope of obviousness-type double patenting for patents in the same family. The Federal Circuit held that a first-filed, first-issued, later-expiring patent claim cannot be invalidated for obvious-type double patenting based on a later-filed, later-issued, earlier-expiring child patent when the patents share a common priority date.
Branded Manufacturers Decline to Remove Patents From the Orange Book After Receiving Letters From the FTC
On Friday, June 21, 2024, the FDA updated its Patent Listing Dispute List to indicate that the ten pharmaceutical companies who had received warning letters from the FTC in April did not make changes to their patent listings in the FDA’s catalog in view of the warning letters.
Knobbe Martens’ Across-the-Board Strength in Patent Work Recognized in IAM 2024 Patent 1000 Guide
IRVINE, Calif., June 21, 2024 – Knobbe Martens is proud to announce that multiple practices across the firm and two dozen partners were recognized nationally and regionally for outstanding work...
FDA Issues Long-Overdue Regulations on Direct-To-Consumer Advertisements for Prescription Medications
On November 21, 2023, the FDA published its final rule changing how prescriptions medicines are advertised to consumers.1 The FDA first issued its proposed rule in 2010, which subsequently went through three public comment periods between 2010 and 2012.2 Interestingly, the FDA provided no opportunities for the public to comment on the rule since 2012. The FDA addressed the over 10-year gap between the last comment opportunity and the issuance of the final rule, explaining that it was due in large part to competing demands for limited Agency resources, including repeated natural disasters, the opioid epidemic, and infectious disease outbreaks including Ebola, Zika, and COVID-19.3 The FDA concluded that no material changes have occurred in the fundamental concepts, scientific research, or literature underlying the proposed rule since 2012.4
LMG Recognizes Knobbe Martens as Leading Life Sciences Firm
IRVINE, CALIF., September 21, 2023 – Knobbe Martens is pleased to announce that Legal Media Group (LMG) has again recognized the firm as having one of the top life sciences intellectual...
IAM 2023 Patent 1000 Guide Recognizes More Than Two Dozen Knobbe Martens Partners and Practices
IRVINE, CALIF., June 26, 2023 – Knobbe Martens is pleased to announce that 23 of the firm’s partners were recognized as leading patent professionals and ranked nationally or regionally in the...
Analogous Art Must Be Compared to the Challenged Patent
In Sanofi-Aventis Deutschland GmbH v. Mylan Pharm. Inc., Case No. 2021-1981, the Federal Circuit reversed an obviousness determination by the PTAB. At issue was Sanofi’s reissued U.S. Patent No. RE47,614 (the ’614 patent), directed to a drug delivery device. The PTAB had found Sanofi’s drug delivery patent to be obvious in view of three prior art references: Burren, Venezia, and de Gennes.
Federal Circuit Finds Patent for Dietary Supplements Invalid Under § 101 for Reciting Naturally Occurring Milk Components
Occurring Milk ComponentsIn ChromaDex, Inc. v Elysium Health, Inc., Appeal No. 2022-1116, the Federal Circuit upheld the invalidity of a claim reciting a supplement comprising nicotinamide riboside (“NR”), a component found in cow’s milk, under 35 U.S.C. § 101, finding that the claim read on a product of nature.
Knobbe Martens Again Ranked Among Nation’s Top Life Sciences Firms by LMG
IRVINE, CALIF., September 26, 2022 – Knobbe Martens is pleased to announce that Legal Media Group (LMG) has again recognized the firm as having one of the top life sciences...
Two Dozen Knobbe Martens Partners and Practices Recognized in IAM Patent 1000 Guide
Knobbe Martens is pleased to announce that 21 of the firm’s partners in offices on both the East and West Coasts were ranked nationally and regionally in the recently released...
Knobbe Martens and 21 Partners Recognized as IP Leaders in 2021 IAM Patent 1000 Guide
Knobbe Martens is pleased to announce that the firm and 21 partners have been recognized as industry leaders in the recently released 2021 edition of IAM’s Patent 1000 guide. Additionally,...
Knobbe Martens Bolsters San Diego Presence with Move to New Office
Knobbe Martens is pleased to announce that as of February 1, 2021, its San Diego office has relocated to a new, almost 50,000 square foot space in Carmel Valley that includes numerous...
Knobbe Martens Recognized as National Leader, 22 Attorneys Named “World’s Leading Patent Professionals” in 2020 IAM Patent 1000
Knobbe Martens and 22 partners in its California, Washington State and Washington, D.C. offices have been recognized this year as industry leaders in the newly released 2020 IAM Patent 1000...
Trade Secrets Or Patents?
Associate Kim Kennedy and Partner Mike Fuller authored “Trade Secrets Or Patents?” which was published in Life Science Leader. Excerpt: Biotechnology companies are in an exceptionally competitive field, with multiple companies competing against...
Partner Mike Fuller was quoted in, “COVID-19 Partnerships Without Formal Contracts Pose Risks, From Potential Liability To IP Issues,” an article published by Pink Sheet.
Partner Mike Fuller was quoted in, “COVID-19 Partnerships Without Formal Contracts Pose Risks, From Potential Liability To IP Issues,” an article published by Pink Sheet. Excerpt: “Biopharma companies are jumping into partnerships...
